5-7-dihydroxy-3-(3-hydroxy-4-methoxybenzyl)-6-methoxychroman-4-one and Retinal-Neovascularization

5-7-dihydroxy-3-(3-hydroxy-4-methoxybenzyl)-6-methoxychroman-4-one has been researched along with Retinal-Neovascularization* in 2 studies

Other Studies

2 other study(ies) available for 5-7-dihydroxy-3-(3-hydroxy-4-methoxybenzyl)-6-methoxychroman-4-one and Retinal-Neovascularization

Article	Year
Synthesis and Biological Evaluation of Novel Homoisoflavonoids for Retinal Neovascularization. Journal of medicinal chemistry, 2015, Jun-25, Volume: 58, Issue:12 Eye diseases characterized by excessive angiogenesis such as wet age-related macular degeneration, proliferative diabetic retinopathy, and retinopathy of prematurity are major causes of blindness. Cremastranone is an antiangiogenic, naturally occurring homoisoflavanone with efficacy in retinal and choroidal neovascularization models and antiproliferative selectivity for endothelial cells over other cell types. We undertook a cell-based structure-activity relationship study to develop more potent cremastranone analogues, with improved antiproliferative selectivity for retinal endothelial cells. Phenylalanyl-incorporated homoisoflavonoids showed improved activity and remarkable selectivity for retinal microvascular endothelial cells. A lead compound inhibited angiogenesis in vitro without inducing apoptosis and had efficacy in the oxygen-induced retinopathy model in vivo. Topics: Angiogenesis Inhibitors; Animals; Cell Proliferation; Humans; Isoflavones; Mice; Retina; Retinal Neovascularization	2015
Homoisoflavanone inhibits retinal neovascularization through cell cycle arrest with decrease of cdc2 expression. Biochemical and biophysical research communications, 2007, Nov-03, Volume: 362, Issue:4 Neovascularization in the eye is the most common cause of blindness in all age groups; retinopathy of prematurity (ROP), diabetic retinopathy, and age-related macular degeneration. Despite current advances in surgical treatments, ROP remains as the most serious problem of vision loss in children. Here, we report that homoisoflavanone, a natural product from Cremastra appendiculata, significantly reduces retinal neovascularization in a mouse model of ROP. Homoisoflavanone inhibited the cell growth of HUVECs, but its cytotoxic effect was not observed in a concentration range of 1-20 microM. HUVECs population gradually increased in G2/M phase and reduced in G0/G1 and S phases after exposure to the compound. Homoisoflavanone decreased the level of cdc2 expression whereas the level of p21WAF1 expression was increased in a dose-dependent manner. These data demonstrate that homoisoflavanone could inhibit retinal neovascularization and be applied in the treatment of other vasoproliferative retinopathies. Topics: Animals; CDC2 Protein Kinase; Cell Cycle; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Humans; Infant, Newborn; Isoflavones; Mice; Mice, Inbred C57BL; Retinal Neovascularization; Retinopathy of Prematurity	2007

Article

Year

Synthesis and Biological Evaluation of Novel Homoisoflavonoids for Retinal Neovascularization.

Journal of medicinal chemistry, 2015, Jun-25, Volume: 58, Issue:12

Eye diseases characterized by excessive angiogenesis such as wet age-related macular degeneration, proliferative diabetic retinopathy, and retinopathy of prematurity are major causes of blindness. Cremastranone is an antiangiogenic, naturally occurring homoisoflavanone with efficacy in retinal and choroidal neovascularization models and antiproliferative selectivity for endothelial cells over other cell types. We undertook a cell-based structure-activity relationship study to develop more potent cremastranone analogues, with improved antiproliferative selectivity for retinal endothelial cells. Phenylalanyl-incorporated homoisoflavonoids showed improved activity and remarkable selectivity for retinal microvascular endothelial cells. A lead compound inhibited angiogenesis in vitro without inducing apoptosis and had efficacy in the oxygen-induced retinopathy model in vivo.

Topics: Angiogenesis Inhibitors; Animals; Cell Proliferation; Humans; Isoflavones; Mice; Retina; Retinal Neovascularization

2015

Homoisoflavanone inhibits retinal neovascularization through cell cycle arrest with decrease of cdc2 expression.

Biochemical and biophysical research communications, 2007, Nov-03, Volume: 362, Issue:4

Neovascularization in the eye is the most common cause of blindness in all age groups; retinopathy of prematurity (ROP), diabetic retinopathy, and age-related macular degeneration. Despite current advances in surgical treatments, ROP remains as the most serious problem of vision loss in children. Here, we report that homoisoflavanone, a natural product from Cremastra appendiculata, significantly reduces retinal neovascularization in a mouse model of ROP. Homoisoflavanone inhibited the cell growth of HUVECs, but its cytotoxic effect was not observed in a concentration range of 1-20 microM. HUVECs population gradually increased in G2/M phase and reduced in G0/G1 and S phases after exposure to the compound. Homoisoflavanone decreased the level of cdc2 expression whereas the level of p21WAF1 expression was increased in a dose-dependent manner. These data demonstrate that homoisoflavanone could inhibit retinal neovascularization and be applied in the treatment of other vasoproliferative retinopathies.

Topics: Animals; CDC2 Protein Kinase; Cell Cycle; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Humans; Infant, Newborn; Isoflavones; Mice; Mice, Inbred C57BL; Retinal Neovascularization; Retinopathy of Prematurity

2007